Dr. Jacqueline Elizabeth Shea Ph.D.

Inovio Pharmaceuticals, Inc.

Dr. Jacqueline Shea has served as INOVIO’s President and CEO since May 2022. A molecular biologist and cell cycle geneticist by training, Jacqueline has dedicated much of her career to developing innovative products to prevent and treat infectious diseases. At INOVIO, she is responsible for establishing and leading overall corporate strategy across its clinical programs and advancing its DNA medicines platform She joined the company as COO, serving as a key member of the executive team and led INOVIO’s manufacturing, commercial, business development, project and alliance management operations. Prior to joining INOVIO, she was the CEO at Aeras where she oversaw two major clinical trial breakthroughs in the development of TB vaccines. Previously, she held executive roles at Emergent BioSolutions and Oxford-Emergent Tuberculosis Consortium. She has been named as an inventor on more than 20 patents, is an author of numerous scientific publications, has served on multiple advisory boards and currently serves on the Board of Trustees for the Sabin Vaccine Institute. She received a BSc Hons in Applied Biology from the University of Bath and a Ph.D. from the National Institute for Medical Research in the UK.

Year appointed: May 2022

Register for this year’s Action for Impact Summit happening on September 25, 2024!